In the latest close session, Veeva Systems (VEEV) was down 2.13% at $276.46. This move lagged the S&P 500's daily gain of 0.54%. Elsewhere, the Dow gained 0.52%, while the tech-heavy Nasdaq added 0.74%. Heading into today, shares of the provider of cloud-based software services for the life sciences industry had gained 0.37% over the past month, outpacing the Medical sector's loss of 2.12% and lagging the S&P 500's gain of 4.2%.Investors will be eagerly watching for the performance of Veeva Systems in its u ...

Key Takeaways Veeva Systems added 28 Vault CRM customers in Q1 FY26, reaching 80 total live deployments. Three of the top 20 global biopharma firms have adopted Veeva Systems' Vault CRM suite. Veeva Systems' CRM Pulse and upcoming AI features aim to deepen platform capabilities by the end of 2025.Veeva Systems (VEEV) is seeing strong momentum in its next-gen Vault CRM (customer relationship management) offering, with fiscal first-quarter 2026 results highlighting rapid customer adoption and strategic posi ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Veeva Systems (VEEV) .Veeva currently has an average brokerage recommendation (ABR) of 1.97, on ...

Core Insights - The Motley Fool aims to enhance the financial literacy and well-being of individuals by providing investment solutions and market analysis [1] Company Overview - Founded in 1993, The Motley Fool is a financial services company focused on making the world smarter, happier, and richer [1] - The company reaches millions of people monthly through various platforms, including premium investing solutions, free guidance, and market analysis on Fool.com [1] - The Motley Fool also produces top-rated podcasts and operates a non-profit organization, The Motley Fool Foundation [1]

Core Insights - Veeva Systems (VEEV) is strategically expanding its partnerships in 2025, enhancing its integration within the life sciences sector and driving growth [1][3][7] Partnerships and Collaborations - In June 2025, Veeva partnered with the Sarah Cannon Research Institute to implement its Clinical Platform at over 200 oncology research sites, validating its technology for cancer trials [1] - Astellas selected Veeva's Vault CRM as its global standard for commercial operations, including a version tailored for China [1] - Veeva collaborated with Zifo in January 2025 to facilitate the integration of lab quality data into Veeva LIMS, expediting system rollouts [1] - EVERSANA joined Veeva's partner program in April 2025 to co-develop generative AI tools for content creation and customer engagement [2] - Partnerships with DNAnexus and Accumulus Synergy have enhanced Veeva's regulatory capabilities, aiding pharma companies in managing global filings [2] Market Position and Performance - Veeva's partnerships are accelerating adoption, strengthening customer relationships, and creating new growth avenues in clinical research, AI engagement, and regulatory compliance [3] - VEEV shares have increased by 33.5% year-to-date, significantly outperforming the industry growth of 8.1% [6][7] Valuation and Earnings Estimates - Veeva trades at a forward price-to-sales ratio of 14.25, which is above the industry average [8] - The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings suggests a 15.8% increase compared to the previous year [9] - Current earnings estimates for the upcoming quarters indicate a year-over-year growth of 17.28% for the current quarter and 15.76% for the current year [10]

Key Takeaways VEEV rose nearly 29% in three months, driven by strong Q1 results. VEEV's Vault CRM has over 80 customers, with plans to more than double that number by the end of 2026. VEEV to launch AI tools like CRM Bot, as Crossix and CRM Pulse see rising adoption among pharma clients.Veeva Systems (VEEV) has been on a strong upswing, with its stock climbing nearly 29% over the past three months. The rally followed the company’s solid earnings for the first quarter of fiscal 2026, where revenues came in ...

Core Viewpoint - The article emphasizes the importance of fundamental analysis in identifying undervalued companies with long-term growth potential, advocating for a value investing approach that focuses on purchasing quality companies at a discount to their intrinsic value and holding them for extended periods to maximize earnings and shareholder returns. Group 1 - The investment strategy combines value investing principles with a focus on long-term growth [1] - The approach involves buying quality companies at a discount to their intrinsic value [1] - The goal is to allow companies to compound their earnings and shareholder returns over time [1]

Core Insights - Veeva Systems is launching Veeva AI, a generative AI layer integrated into its Vault platform to enhance automation and efficiency for life sciences companies [1][6] - The integration of AI aims to improve productivity and decision-making in clinical, quality, and regulatory functions, thereby increasing customer reliance on Veeva's software [2][6] - Veeva is experiencing steady financial performance and geographic expansion, particularly in China, positioning itself as a key technology provider as life sciences firms adopt AI [2] Competitive Landscape - IQVIA Holdings is also investing in AI, utilizing its Orchestrated Clinical Trials platform to enhance trial planning and patient recruitment, showcasing a different approach by combining data, analytics, and services [3] - Schrodinger Inc. is leveraging AI in drug discovery, focusing on deep learning and molecular simulation to optimize drug compounds, thus complementing Veeva's offerings in the life sciences ecosystem [4] Financial Performance - Veeva's shares have increased by 34.6% year-to-date, outperforming the industry growth of 22.5% [5][6] - The company has a forward price-to-sales ratio of 14.25, which is above the industry average, indicating a premium valuation [8] - The Zacks Consensus Estimate predicts a 15.8% rise in Veeva's fiscal 2026 earnings compared to the previous year [9]

Core Viewpoint - The healthcare sector is highlighted as a critical area in the stock market, driven by the need for innovative therapies and medical technologies to address an aging population and rising chronic diseases. There are ten under-the-radar healthcare stocks identified as potential investment opportunities. Group 1: Company Highlights - **Certara**: Positioned to benefit from AI-driven transformations in medicine, providing bio-simulation software that accelerates drug development, with over 90% of novel drugs approved by the FDA since 2014 utilizing its technology [3][4]. - **Beam Therapeutics**: A clinical-stage biotech focusing on precision gene editing therapies for genetic diseases, with its lead candidate in phase 1/2 trials for sickle cell disease, showing promise for long-term growth [5][6]. - **Inspire Medical Systems**: Develops implantable devices for obstructive sleep apnea, reporting a 23% year-over-year revenue increase to $201 million, indicating strong market demand [8]. - **Insulet**: Specializes in tubeless insulin pump technology, targeting a revenue growth of 19% to 22% by 2025, with significant expansion opportunities in international markets [9]. - **Krystal Biotech**: Focuses on rare skin diseases, with its gene therapy expected to generate approximately $400 million in revenue this year, reinforcing its market position [10]. - **LifeMD**: Operates a telehealth platform with a 49% year-over-year revenue increase, driven by a partnership with Novo Nordisk, indicating potential for further growth [11]. - **Option Care Health**: Leading provider of home infusion services, positioned to benefit from the shift towards personalized healthcare [12]. - **Tempus AI**: Utilizes AI for precision medicine, projecting over 80% revenue growth this year to about $1.3 billion, highlighting its expansive data ecosystem [13]. - **TransMedics Group**: Innovates in organ transplantation with its FDA-approved Organ Care System, projecting a 30% revenue growth this year [14][15]. - **Veeva Systems**: Offers cloud-based software for life sciences, serving over 1,000 customers and positioned to capitalize on the industry's digital transformation [16].

It has been about a month since the last earnings report for Veeva Systems (VEEV) . Shares have added about 0.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Veeva due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns ...